|
Orthologous residues
|
|
PPAR‑gamma (human): S112‑p, PPAR‑gamma (mouse): S112‑p, PPAR‑gamma iso2 (mouse): S82‑p, PPAR‑gamma (rat): S112‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, electrophoretic mobility shift, mutation of modification site
|
|
Relevant cell lines - cell types - tissues:
293T (epithelial), 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout]
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, mouse
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
EGF
|
|
|
|
increase
|
|
|
PD98059
|
EGF
|
|
|
inhibit treatment-induced increase
|
|
|
rosiglitazone
|
EGF
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (process):
transcription, altered
|
